Suppr超能文献

瑞德西韦治疗儿童急性 2019 冠状病毒病合并窦性心动过缓:病例报告及文献复习。

Sinus Bradycardia in a Pediatric Patient Treated With Remdesivir for Acute Coronavirus Disease 2019: A Case Report and a Review of the Literature.

机构信息

Department of Medicine, Division of Allergy and Infectious Diseases, University of Washington, Seattle, Washington, USA.

Department of Pediatrics, Division of Infectious Diseases, Seattle Children's Hospital and University of Washington, Seattle, Washington, USA.

出版信息

J Pediatric Infect Dis Soc. 2021 Oct 27;10(9):926-929. doi: 10.1093/jpids/piab029.

Abstract

Remdesivir is an RNA polymerase inhibitor that is commonly used in the treatment of patients with severe acute coronavirus disease 2019 (COVID-19). As the severe acute respiratory syndrome coronavirus 2 spreads, the use of remdesivir is likely to increase. Most of the patients treated with remdesivir will not experience any adverse events although some side effects have been reported. Here, we describe a case of sinus bradycardia associated with remdesivir therapy in a pediatric patient with severe acute COVID-19.

摘要

瑞德西韦是一种 RNA 聚合酶抑制剂,常用于治疗严重急性 2019 冠状病毒病(COVID-19)患者。随着严重急性呼吸综合征冠状病毒 2 的传播,瑞德西韦的使用可能会增加。虽然有报道称瑞德西韦治疗的部分患者出现了一些副作用,但大多数患者不会出现任何不良反应。在此,我们描述了一例严重急性 COVID-19 儿科患者在接受瑞德西韦治疗时出现窦性心动过缓的病例。

相似文献

2
Remdesivir-associated bradycardia.
BMJ Case Rep. 2021 Sep 3;14(9):e245289. doi: 10.1136/bcr-2021-245289.
4
Severe sinus bradycardia associated with remdesivir in a child with severe SARS-COV-2 infection-reply.
Eur J Pediatr. 2021 May;180(5):1629-1630. doi: 10.1007/s00431-021-03952-0. Epub 2021 Jan 19.
5
Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection.
Eur J Pediatr. 2021 May;180(5):1627. doi: 10.1007/s00431-021-03940-4. Epub 2021 Jan 23.
6
Sinus Bradycardia in Children Treated With Remdesivir for COVID-19.
Pediatr Infect Dis J. 2021 Sep 1;40(9):e356. doi: 10.1097/INF.0000000000003214.
7
Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.
Expert Opin Drug Saf. 2021 Dec;20(12):1559-1564. doi: 10.1080/14740338.2021.1962846. Epub 2021 Aug 5.
8
Remdesivir, Sinus Bradycardia and Therapeutic Drug Monitoring in Children With Severe COVID-19.
Pediatr Infect Dis J. 2021 Dec 1;40(12):e528-e529. doi: 10.1097/INF.0000000000003309.
9
Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19).
J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.05.025. Epub 2021 May 28.

引用本文的文献

1
Remdesivir Use in Pediatric Patients with Acute SARS-CoV-2 Infection Is Safe and Well Tolerated.
Children (Basel). 2025 Mar 6;12(3):331. doi: 10.3390/children12030331.
2
COVID-19 and Cardiac Arrhythmias: Lesson Learned and Dilemmas.
J Clin Med. 2024 Nov 29;13(23):7259. doi: 10.3390/jcm13237259.
3
Electrophysiological Profile of Different Antiviral Therapies in a Rabbit Whole-Heart Model.
Cardiovasc Toxicol. 2024 Jul;24(7):656-666. doi: 10.1007/s12012-024-09872-3. Epub 2024 Jun 8.
4
Remdesivir: treatment of COVID-19 in special populations.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Jun;397(6):3829-3855. doi: 10.1007/s00210-023-02927-2. Epub 2024 Jan 5.
5
Remdesivir therapy for severe pediatric COVID-19 in Singapore: A single-center retrospective observational cohort study.
Health Sci Rep. 2023 Dec 14;6(12):e1698. doi: 10.1002/hsr2.1698. eCollection 2023 Dec.
7
Remdesivir: the first FDA-approved anti-COVID-19 Treatment for Young Children.
Discoveries (Craiova). 2022 Jun 30;10(2):e151. doi: 10.15190/d.2022.10. eCollection 2022 Apr-Jun.
9
Severe Acute Respiratory Syndrome Coronavirus 2 Infections in Children.
Infect Dis Clin North Am. 2022 Jun;36(2):435-479. doi: 10.1016/j.idc.2022.01.005. Epub 2022 Feb 1.
10
Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19.
Vaccines (Basel). 2022 Mar 8;10(3):405. doi: 10.3390/vaccines10030405.

本文引用的文献

2
Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.
Clin Microbiol Infect. 2021 Feb 27;27(5):791.e5-8. doi: 10.1016/j.cmi.2021.02.013.
3
Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection.
Eur J Pediatr. 2021 May;180(5):1627. doi: 10.1007/s00431-021-03940-4. Epub 2021 Jan 23.
4
Cardiac Adverse Events With Remdesivir in COVID-19 Infection.
Cureus. 2020 Oct 24;12(10):e11132. doi: 10.7759/cureus.11132.
5
Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.
JACC Case Rep. 2020 Nov 18;2(14):2260-2264. doi: 10.1016/j.jaccas.2020.08.025. Epub 2020 Oct 28.
6
Remdesivir for the Treatment of Covid-19 - Final Report.
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
7
Drug-induced mitochondrial dysfunction and cardiotoxicity.
Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67. doi: 10.1152/ajpheart.00554.2015. Epub 2015 Sep 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验